Liminatus Pharma, Inc. (LIMN)
Nasdaq: LIMN · Biological Products, (No Diagnostic Substances) · Cerritos, CA · filing with the SEC since 2023
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 |
| Report filed | Mar 31, 2026 | · |
| Research and development | · | 2,685,334 |
| General and administrative | 2,967,812 | 644,619 |
| Total operating expenses | 2,967,812 | 3,329,953 |
| Operating income | -2,967,812 | -3,329,953 |
| Interest expense | 215,903 | 338,882 |
| Interest and investment income | 76,589 | 122,526 |
| Total non-operating income (expense) | -7,238,705 | -216,356 |
| Net income including non-controlling interests | -10,206,517 | -3,546,309 |
| Net income | -10,206,517 | -3,546,309 |
| Earnings per share, basic | -0.43 | -0.20 |
| Earnings per share, diluted | -0.43 | -0.20 |
| Weighted average shares, basic | 23,753,561 | 17,500,000 |
| Weighted average shares, diluted | 23,753,561 | 17,500,000 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding